Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis

References

• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109–1122. Epub 2015 Sep 13. PMID: 26377142.
   PubMed Web of Science ®Google Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. Epub 2015 Apr 24. PMID: 25925336
   PubMed Web of Science ®Google Scholar
• Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;8:S115–S123.
   Google Scholar
• Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in america study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019 Mar;139(3):583–590. Epub 2018 Oct 30. PMID: 30389491.
   PubMed Web of Science ®Google Scholar
• Waldman AR, Ahluwalia J, Udkoff J, et al. Atopic Dermatitis. Pediatr Rev. 2018 Apr;39(4):180–193. PMID: 29610426
   PubMed Web of Science ®Google Scholar
• Girolomoni G, Luger T, Nosbaum A, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey. Dermatol Ther (Heidelb). 2021 Feb;11(1):117–130. Epub 2020 Nov 12. PMID: 33180320; PMCID: PMC7858996
   PubMed Web of Science ®Google Scholar
• Drucker AM, Qureshi AA, Amand C, et al. Health care resource utilization and costs among adults with atopic dermatitis in the United States: a claims-based analysis. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1342–1348. Epub 2017 Nov 22. PMID: 29174063
   PubMed Web of Science ®Google Scholar
• Luger T, Dirschka T, Eyerich K, et al. Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019. J Eur Acad Dermatol Venereol. 2020 Dec;34(Suppl 7):3–18. PMID: 33315305
   PubMedGoogle Scholar
• Singh R, Heron CE, Ghamrawi RI, et al. Emerging role of Janus Kinase inhibitors for the treatment of atopic dermatitis. Immunotargets Ther. 2020 Nov 10;9:255–272. PMID: 33204661; PMCID: PMC7667501.
   PubMed Web of Science ®Google Scholar
• Rodenbeck DL, Silverberg JI, Silverberg NB. Phototherapy for atopic dermatitis. Clin Dermatol. 2016 Sep-Oct;34(5):607–613. Epub 2016 May 20. PMID: 27638440
   PubMed Web of Science ®Google Scholar
• Diaz A, Guttman-Yassky E. Topical agents for the treatment of atopic dermatitis. Expert Rev Clin Immunol. 2019 Apr;15(4):369–382. Epub 2019 Jan 8. PMID: 30587053
   PubMed Web of Science ®Google Scholar
• Abędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Postepy Dermatol Alergol. 2019 Dec;36(6):752–759. Epub 2019 Dec 30. PMID: 31998006; PMCID: PMC6986278
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits. J Dermatol. 2018 Aug;45(8):936–942. Epub 2018 Jun 21. PMID: 29927498; PMCID: PMC6099320
   PubMed Web of Science ®Google Scholar
• Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021 Jan;126(1):21–31. Epub 2020 Aug 17. PMID: 32818591
   PubMed Web of Science ®Google Scholar
• Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020 Mar;16(3):133–144. Epub 2020 Feb 7. PMID: 32034322
   PubMed Web of Science ®Google Scholar
• Mueller SM, Itin P, Vogt DR, et al. Assessment of “corticophobia” as an indicator of non-adherence to topical corticosteroids: a pilot study. J Dermatolog Treat. 2017 Mar;28(2):104–111. Epub 2016 Jul 10. PMID: 27396480
   PubMed Web of Science ®Google Scholar
• Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333–343. Epub 2017 Dec 8. PMID: 29216643.
   PubMed Web of Science ®Google Scholar
• Bieber T, D’Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017 Apr;139(4S):S58–S64. PMID: 28390478
   PubMed Web of Science ®Google Scholar
• Litman T. Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases. APMIS. 2019 May;127(5):386–424. PMID: 31124204; PMCID: PMC6851586
   PubMed Web of Science ®Google Scholar
• Ghosh D, JA B, Khurana HGK, et al. Leveraging multilayered “omics” data for atopic dermatitis: a road map to precision medicine. Front Immunol. 2018 Dec 12;9:2727. PMID: 30631320; PMCID: PMC6315155.
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017 Mar 7;7(1):1–23. Epub 2016 Dec 26. PMID: 28025775; PMCID: PMC5336433.
   PubMed Web of Science ®Google Scholar
• Fabbrocini G, Napolitano M, Megna M, et al. Treatment of atopic dermatitis with biologic drugs. Dermatol Ther (Heidelb). 2018 Dec;8(4):527–538. Epub 2018 Sep 4. PMID: 30182182; PMCID: PMC6261117
   PubMed Web of Science ®Google Scholar
• Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020 Feb;31(1):33–40. Epub 2019 Feb 18. PMID: 30703333
   PubMed Web of Science ®Google Scholar
• Szalus K, Trzeciak M, Nowicki RJ. JAK-STAT inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms. 2020 Nov 6;8(11):1743. PMID: 33172122; PMCID: PMC7694787.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019 Mar 1;40(2):84–92. PMID: 30819278; PMCID: PMC6399565.
   PubMed Web of Science ®Google Scholar
• New DA. Treatments for atopic dermatitis targeting skin barrier repair via the regulation of FLG expression. J Clin Med. 2021 Jun 5;10(11):2506. PMID: 34198894; PMCID: PMC8200961.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Maurelli M, Peris K, et al. Targeting IL-4 for the treatment of atopic dermatitis. Immunotargets Ther. 2020 Sep 29;9:151–156. PMID: 33062619; PMCID: PMC7532907.
   PubMed Web of Science ®Google Scholar
• Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020 May;75(5):1188–1204. Epub 2020 Jan 3. PMID: 31838750; PMCID: PMC7317958
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016 Nov;175(5):902–911. Epub 2016 Sep 24. PMID: 27423107
   PubMed Web of Science ®Google Scholar
• Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020 Jun;82(6):1305–1313. Epub 2020 Feb 11. PMID: 32057960
   PubMed Web of Science ®Google Scholar
• Kim BS, Howell MD, and Sun K, et al. INCB 18424-206 study investigators. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020 Feb;145(2):572–582. Epub 2019 Oct 17. PMID: 31629805.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021 Jun 10: S0190-9622(21)01116-6. Epub ahead of print. PMID: 34118298. DOI:https://doi.org/10.1016/j.jaad.2021.06.014.
   Google Scholar
• Damsky W, BA K. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017 Apr;76(4):736–744. Epub 2017 Jan 28. PMID: 28139263; PMCID: PMC6035868
   PubMed Web of Science ®Google Scholar
• Spinelli FR, Meylan F, O’Shea JJ, et al. JAK inhibitors: ten years after. Eur J Immunol. 2021 Jul;51(7):1615–1627. Epub 2021 May 31. PMID: 33930196
   PubMed Web of Science ®Google Scholar
• Virtanen A T, Haikarainen T, Raivola J, et al. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019 Feb;33(1):15–32. PMID: 30701418; PMCID: PMC6373396
   PubMed Web of Science ®Google Scholar
• Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021 Jan;80(1):71–87. Epub 2020 Nov 6. PMID: 33158881; PMCID: PMC7788060
   PubMed Web of Science ®Google Scholar
• LK O, MR M, Feng J, et al. Sensory neurons Co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017 Sep 21;171(1):217–228.e13. Epub 2017 Sep 7. PMID: 28890086; PMCID: PMC5658016.
   PubMed Web of Science ®Google Scholar
• Alves de Medeiros AK, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016 Oct 6;11(10):e0164080. PMID: 27711196; PMCID: PMC5053514.
   PubMed Web of Science ®Google Scholar
• Ciechanowicz P, Rakowska A, Sikora M, et al. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatolog Treat. 2019 Nov;30(7):648–658. Epub 2018 Dec 3. PMID: 30433838
   PubMed Web of Science ®Google Scholar
• Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol. 2018 Sep;79(3):535–544. Epub 2018 Apr 16. PMID: 29673776.
   PubMed Web of Science ®Google Scholar
• Svoboda SA, Johnson N, Phillips M. Dermatologic applications and safety considerations of Janus Kinase inhibitors. Skin Therapy Lett. 2020 Sep;25(4):6–11. PMID: 33017108
   PubMedGoogle Scholar
• Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol. 2017 Jan;13(1):15–26. Epub 2016 Jul 28. PMID: 27417220; PMCID: PMC5216178
   PubMed Web of Science ®Google Scholar
• Cabanillas B, Brehler AC, Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):309–315. PMID: 28582322; PMCID: PMC5515628
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338–351. Epub 2013 Nov 27. PMID: 24290431; PMCID: PMC4410183
   PubMed Web of Science ®Google Scholar
• Weidinger S, Baurecht H, Schmitt J. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. Br J Dermatol. 2017 Oct 4;177:999–1003. Epub 2017 Sep 4. PMID: 28868633.
   PubMed Web of Science ®Google Scholar
• McDowell L, Olin B. Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis. J Pharm Technol. 2019;35:172–178.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014 Jul;71(1):116–132. Epub 2014 May 9. PMID: 24813302; PMCID: PMC4326095
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Pavel AB, McHale K, et al. A Phase 1b, randomized, single-center trial of topical cerdulatinib (DMVT-502) in patients with mild-to-moderate atopic dermatitis. J Invest Dermatol. 2021 Jul;141(7):1847–1851. Epub 2021 Jan 22. PMID: 33493530
   PubMed Web of Science ®Google Scholar
• Tegtmeyer K, Ravi M, Zhao J, et al. Off-label studies on the use of ruxolitinib in dermatology. Dermatitis. 2021 May-Jun 1;32(3):164–172. PMID: 33443378.
   PubMedGoogle Scholar
• Wu J, Smogorzewski J. Off-label studies on ruxolitinib in dermatology: a review. J Dermatolog Treat. 2020 Jun 9:1–7. Epub ahead of print. PMID: 32515635. DOI:https://doi.org/10.1080/09546634.2020.1773385.
   Google Scholar
• Scuron MD, Fay BL, Connell AJ, et al. Ruxolitinib cream has dual efficacy on pruritus and inflammation in experimental dermatitis. Front Immunol. 2021 Feb 15;11:620098. PMID: 33658996; PMCID: PMC7917252.
   PubMed Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 May 4:S0190-9622(21)00931–2. Epub ahead of print. PMID: 33957195. DOI:https://doi.org/10.1016/j.jaad.2021.04.085.
   Google Scholar
• Worm M, Bauer A, and Elsner P, et al. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol. 2020 May;182(5):1103–1110. Epub 2019 Nov 8. PMID: 31466119.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Dec;144(6):1575–1583. Epub 2019 Aug 16. PMID: 31425780
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018 Feb;178(2):424–432.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020 Feb;47(2):114–120. Epub 2019 Dec 9. PMID: 31820485; PMCID: PMC7028108.
   PubMed Web of Science ®Google Scholar
• Gong X, Chen X, Kuligowski ME, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from Phase II and III studies. Am J Clin Dermatol. 2021 Jul;22(4):555–566. Epub 2021 May 12. PMID: 33982267; PMCID: PMC8200345.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Delgocitinib: first Approval. Drugs. 2020 Apr;80(6):609–615. PMID: 32166597
   PubMed Web of Science ®Google Scholar
• Noji S, Hara Y, Miura T, et al. Discovery of a Janus Kinase inhibitor bearing a highly three-dimensional spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders. J Med Chem. 2020 Jul 9;63(13):7163–7185. Epub 2020 Jun 29. PMID: 32511913.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He H, Krueger JG, et al. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019 Jan;143(1):1–11. PMID: 30612663
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Otsuka A, Nakashima C, et al. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model. J Dermatol Sci. 2020 Feb;97(2):161–164. Epub 2019 Dec 20. PMID: 31924380
   PubMed Web of Science ®Google Scholar
• Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents. Exp Dermatol. 2018 Jan;27(1):22–29. Epub 2017 Jul 3. PMID: 28423239
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020 Apr;82(4):823–831. Epub 2020 Feb 3. Erratum in: J Am Acad Dermatol. 2021 Jul 10;: PMID: 32029304
   PubMed Web of Science ®Google Scholar
• Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic Hand Eczema: successes and key challenges. Ther Clin Risk Manag. 2020 Dec 31;16:1319–1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233.PMID: 33408476; PMCID: PMC7780849.
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Ehling S, Wilzopolski J, et al. Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model. BMC Pharmacol Toxicol. 2018 Jul 3;19(1):37. PMID: 29970189; PMCID: PMC6029395.
   PubMedGoogle Scholar
• Fukuyama T, Ehling S, Cook E, et al. Topically administered Janus-Kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther. 2015 Sep;354(3):394–405. Epub 2015 Jul 9. PMID: 26159873
   PubMed Web of Science ®Google Scholar
• Purohit VS, Ports WC, and Wang C, et al. Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning. J Clin Pharmacol. 2019 Jun;59(6):811–820. Epub 2018 Dec 17. PMID: 30556911; PMCID: PMC6590358.
   PubMed Web of Science ®Google Scholar